Avutometinib Potassium 0.8 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.8 mg, 200 mg

Reference Brands: Avmapki (USA), Fakzynja (USA)

Category: Oncology Cancer Care

Avutometinib Potassium is a Oncology Cancer Care product available as Capsules in strengths 0.8 mg, 200 mg. It corresponds to the reference brands Avmapki (USA), Fakzynja (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Avutometinib potassium (CH5126766) is a small-molecule kinase inhibitor designed to block the RAF/MEK signaling pathway in cancer cells. It functions as a RAF/MEK clamp, potently inhibiting RAF and MEK kinase activity while inducing dominant-negative RAF-MEK complexes that prevent MEK phosphorylation by ARAF, BRAF, and CRAF. This mechanism effectively suppresses tumor cell proliferation, particularly in cell lines harboring KRAS mutations, including pancreatic ductal adenocarcinoma (PDAC) models. Preclinical studies demonstrate that Avutometinib potassium inhibits tumor growth and improves survival in KRAS/p53 pancreatic cancer mouse models. The compound shows promise for targeted therapy research in low-grade serous ovarian carcinoma (LGSOC), ovarian cancer, and pancreatic cancers, offering a precision oncology approach to treatment. Administered orally in capsule form, Avutometinib potassium is being investigated both as a single agent and in combination therapies to enhance anti-cancer efficacy. Its ability to disrupt critical cancer cell signaling pathways highlights its potential as a valuable therapeutic option in the development of next-generation treatments for KRAS-driven malignancies.